Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.
Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week.
In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that an investigator-led Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb's PD-1 drug, would begin.
Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J; is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.
Aduro BioTech's GVAX, a previously failed cancer vaccine, is finding new life in a combination treatment that the Berkeley-based company is testing in patients with pancreatic cancer.
Aduro BioTech has gained access to BioSante Pharmaceuticals' GVAX pancreas cancer vaccine and GVAX prostate cancer vaccine through a licensing agreement. The Berkeley, CA-based company plans to